133 related articles for article (PubMed ID: 10194656)
1. Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin-converting enzyme inhibitor fosinopril in congestive heart failure.
Galatius S; Wroblewski H; Sørensen V; Haunsø S; Nørgaard T; Kastrup J
J Card Fail; 1999 Mar; 5(1):17-24. PubMed ID: 10194656
[TBL] [Abstract][Full Text] [Related]
2. Treatment of heart failure with fosinopril: an angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion.
Mancia G; Giannattasio C; Grassi G
Am J Hypertens; 1997 Oct; 10(10 Pt 2):236S-241S. PubMed ID: 9366279
[TBL] [Abstract][Full Text] [Related]
3. The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group.
Sharma S; Deitchman D; Eni JS; Gelperin K; Ilgenfritz JP; Blumenthal M
Am J Ther; 1999 Jul; 6(4):181-9. PubMed ID: 11329095
[TBL] [Abstract][Full Text] [Related]
4. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial.
Drexler H; Banhardt U; Meinertz T; Wollschläger H; Lehmann M; Just H
Circulation; 1989 Mar; 79(3):491-502. PubMed ID: 2521816
[TBL] [Abstract][Full Text] [Related]
5. Treatment of congestive heart failure: experience with fosinopril.
Blumenthal M
Am J Hypertens; 1997 Oct; 10(10 Pt 2):289S-298S. PubMed ID: 9366286
[TBL] [Abstract][Full Text] [Related]
6. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril.
Galatius-Jensen S; Wroblewski H; Emmeluth C; Bie P; Haunsø S; Kastrup J
Cardiovasc Res; 1996 Dec; 32(6):1148-54. PubMed ID: 9015418
[TBL] [Abstract][Full Text] [Related]
7. Fosinopril versus enalapril in the treatment of hypertension: a double-blind study in 195 patients.
Hansson L; Forslund T; Höglund C; Istad H; Lederballe-Pedersen O; Kristinsson A; Segaard E; Svensson A; Aärynen M; Wahrenberg H; Wennersten G; Kjellström T
J Cardiovasc Pharmacol; 1996 Jul; 28(1):1-5. PubMed ID: 8797128
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.
Cesari M; Kritchevsky SB; Atkinson HH; Penninx BW; Di Bari M; Tracy RP; Pahor M
Am Heart J; 2009 Feb; 157(2):334.e1-8. PubMed ID: 19185642
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
[TBL] [Abstract][Full Text] [Related]
10. Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure.
Davis R; Coukell A; McTavish D
Drugs; 1997 Jul; 54(1):103-16. PubMed ID: 9211084
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD.
Shrikrishna D; Tanner RJ; Lee JY; Natanek A; Lewis A; Murphy PB; Hart N; Moxham J; Montgomery HE; Kemp PR; Polkey MI; Hopkinson NS
Chest; 2014 Oct; 146(4):932-940. PubMed ID: 24556825
[TBL] [Abstract][Full Text] [Related]
12. Regression of left ventricular wall thickness during ACE-inhibitor treatment of essential hypertension is associated with an increase in insulin mediated skeletal muscle blood flow.
Andersson PE; Lind L; Andrén B; Hänni A; Reneland R; Berne C; Lithell H
Blood Press; 1998 May; 7(2):118-26. PubMed ID: 9657539
[TBL] [Abstract][Full Text] [Related]
13. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1.
Pahor M; Franse LV; Deitcher SR; Cushman WC; Johnson KC; Shorr RI; Kottke-Marchant K; Tracy RP; Somes GW; Applegate WB
Circulation; 2002 Jan; 105(4):457-61. PubMed ID: 11815428
[TBL] [Abstract][Full Text] [Related]
14. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
[TBL] [Abstract][Full Text] [Related]
15. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group.
Erhardt L; MacLean A; Ilgenfritz J; Gelperin K; Blumenthal M
Eur Heart J; 1995 Dec; 16(12):1892-9. PubMed ID: 8682023
[TBL] [Abstract][Full Text] [Related]
16. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.
van Wijngaarden J; Smit AJ; de Graeff PA; van Gilst WH; van der Broek SA; van Veldhuisen DJ; Lie KI; Wesseling H
J Cardiovasc Pharmacol; 1994 Feb; 23(2):240-5. PubMed ID: 7511753
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis.
Weinberg EO; Schoen FJ; George D; Kagaya Y; Douglas PS; Litwin SE; Schunkert H; Benedict CR; Lorell BH
Circulation; 1994 Sep; 90(3):1410-22. PubMed ID: 8087951
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the first dose response of fosinopril and captopril in congestive heart failure: a randomized, double-blind, placebo controlled study.
Eryonucu B; Koldas L; Ayan F; Keser N; Sirmaci A
Jpn Heart J; 2001 Mar; 42(2):185-91. PubMed ID: 11384079
[TBL] [Abstract][Full Text] [Related]
19. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
Pu Q; Larouche I; Schiffrin EL
Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
[TBL] [Abstract][Full Text] [Related]
20. Effects of spirapril and captopril on regional blood flow in chronic congestive heart failure: a comparison between a short- and a long-acting angiotensin-converting enzyme inhibitor.
van den Broek SA; de Graeff PA; Smit AJ; Girbes AR; Journée ; van Gilst WH; Hillege H; van Veldhuisen DJ; Wesseling H; Lie KI
J Cardiovasc Pharmacol; 1995 Jan; 25(1):105-12. PubMed ID: 7723338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
